cslbehring.com.au

cslbehring.se

Von Willebrand Disease

http://www.cslbehring.se/s1/cs/bese/1252899238848/content/1252899231141/content.htm

Include All CSL Behring Country Sites. Physicians & Health Care Professionals. Patients & Families. Haemolytic disease of the newborn. Congenital Factor XIII Deficiency. People with von Willebrand disease. VWD) have a problem with one of the clotting factors in the blood; this particular clotting factor is known as von Willebrand factor. In people unaffected by von Willebrand disease, this clotting factor helps platelets stick to the wall of the damaged blood vessel and assists the glue-like clotting.

cslbehring.com

Immunoglobulin, IVIg & SCIg | CSL Behring

http://www.cslbehring.com/s1/cs/enco/1255923358055/page/1255923357721/TabsLandingPage.htm

All CSL Behring Web Sites. Health, Safety & Environment. Quality & Safety. CSL Research & Development. Other Areas of Business. CSL Behring offers one of the world's most comprehensive portfolios of safe, high quality, technically advanced immunoglobulin (Ig) products designed to offer patients the convenience, choice, and ease of administration that they seek. The body's immune system can then work more effectively. CSL Behring Immunoglobulin Products. The CSL Behring product portfolio includes key immu...

cslbehring.se

Physicians & Health Care Professionals

http://www.cslbehring.se/s1/cs/bese/1164719155492/content/1164719155034/content.htm

Include All CSL Behring Country Sites. Physicians & Health Care Professionals. CSL Behring Nordic VW Scholarship. Patients & Families. Physicians and Health Care Professionals. Physicians and Health-care Professionals. Welcome to our section for physicians and health-care professionals. Here you will find information about our medicinal products as well as access to scientific literature, and links to further relevant information. The Patient and Families. If you have any questions.

cslbehring.se

Privacy Policy

http://www.cslbehring.se/s1/cs/bese/1160484846607/content/1160484846331/content.htm

Include All CSL Behring Country Sites. Physicians & Health Care Professionals. Patients & Families. Thank you for visiting www.cslbehring.se. Information Collected from You. How to Contact Us. Information Collected from You. Only when you specifically request it will the information that we collect be used to respond to your questions, or to fulfill e-mail messaging programs, and notify visitors about new content or services on our Web sites. The domain and host from which you access the Internet. You ma...

cslbehring.com

CSL Behring: Global Life Saving Biotherapies, Plasma Protein Biotherapeutics

http://www.cslbehring.com/s1/cs/enco/1151443990667/content/1151443991017/home.htm

All CSL Behring Web Sites. Health, Safety & Environment. Quality & Safety. CSL Research & Development. Other Areas of Business. CSL Behring develops, manufactures and markets protein based therapies, including:. Hereditary Angioedema (HAE) Therapies. Paul Perreault Talks About Innovation. Paul Perreault on Bloomberg News: "If you're not innovating in this rare disease space, you're planning your exit.". Tim’s Story: Outdoor Adventurer Remains Active Despite Hemophilia.

csl.com.au

CSL completes Novartis influenza vaccine business acquisition

http://www.csl.com.au/Investors/CSL-Completes-Novartis-Influenza-Vaccine-Business-Acquisition.htm

CSL Plasma Services (Germany). R&D and Operational Briefings. CSL completes Novartis influenza vaccine business acquisition. CSL completes Novartis influenza vaccine business acquisition. CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million. As foreshadowed in CSL’s release to the Australian Securities Exchange on 31 July. For further information, please contact:.

csl.com.au

CSL - Financial Reports

http://www.csl.com.au/investors/financial-reports.htm

CSL Plasma Services (Germany). R&D and Operational Briefings. Half Year Report 2015-2016. As CSL reaches a remarkable milestone this year, marking 100 years of developing and delivering innovations to help patients live life to the fullest, I am pleased to report an exceptional first half year result. For the six months ended 31 December 2015, CSL reported net profit after tax of US$719 million, an increase of US$27 million (4% on a reported basis) on the same period last year. Half Year Report 2015-2016.

cslbehring.com

CSL Behring: Professor Heimburger Award, Global Research Grant Coagulation

http://www.cslbehring.com/products/bleeding-disorders/professor-heimburger-award.htm

All CSL Behring Web Sites. Health, Safety & Environment. Quality & Safety. CSL Research & Development. Other Areas of Business. CSL Behring Prof. Heimburger Award. Global Research Grant Coagulation. Award Winners (2008 2015). For inquiries regarding applications, policy and procedures information, please contact:. T: 49 6421 394191. E-mail: heimburger.award@cslbehring.com. Prof Heimburger Award 2016:. Professor Dr. Norbert Heimburger. Due to his determination and his constant interaction with leading hem...

cslbehring-us.com

NHF Awards CSLB its 2015 Corporate Leadership Award

http://www.cslbehring-us.com/newsroom/NHF-Awards-CSL-Behring-its-2015-Corporate-Leadership-Award

CSL Behring US Web Sites. Include All CSL Behring Country Sites. National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award. CSL Behring Recognized for its Longstanding Commitment to Delivering Innovative Products and Programs that Advance the Care of the Bleeding Disorders Community. NEW YORK and KING OF PRUSSIA, Pa. — 22 May 2015. Left to right: NHF CEO Val Bias, CSL Limited CEO and Managing Director Paul Perreault, and veteran news broadcaster Jodi Applegate. The National Hemoph...